Guobang Pharma's (SHA:605507) subsidiary, Zhejiang Dongying, received approval from China's National Medical Products Administration to domestically produce its Cefuroxime Axetil Active Pharmaceutical Ingredient (API), according to a Friday filing with the Shanghai Bourse.
The antibiotic treats respiratory, skin, and gonococcal infections. The API is also certified by the European EDQM.